Under the partnership, Bruker will support Biodesix’s multivariate serum protein test and future diagnostic tests that are based on matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.

The VeriStrat serum protein test helps oncologists to provide personalize therapy for patients with lung cancer, while MALDI-TOF mass spectrometry provides detailed and discriminating information about complex biological samples.

Bruker will receive avenues for supporting hardware and software/applications as well as gain access to the latest in instrument designs and improvements.

Biodesix product development and lab operations head Gary Pestano said, "The support we receive from Bruker will substantially benefit both the delivery and development of our diagnostic tests."